Vanta Bioscience Limited

VANTABIO6

INE695X01011

Biotechnology & Medical Research

Delayed Bombay S.E. Other stock markets 02:12:20 2024-04-29 am EDT			5-day change	1st Jan Change
66.15 ^INR	+5.00%		+9.72%	+23.53%

Apr. 03	Vanta Bioscience Bags INR12 Million Order to Conduct Technical Studies	MT
Apr. 02	Vanta Bioscience Limited Receives an Order of INR 12 Million from A Large Indian Multinational Company	CI

Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance Officer

September 03, 2022 at 01:16 pm EDT

Vanta Bioscience Limited announced the resignation of Mr. Zoheb S Sayani as the Company Secretary and Compliance officer of the Company w.e.f.15.09.2022 due to his pre-occupations.

Latest news about Vanta Bioscience Limited

Vanta Bioscience Bags INR12 Million Order to Conduct Technical Studies	Apr. 03	MT
Vanta Bioscience Limited Receives an Order of INR 12 Million from A Large Indian Multinational Company	Apr. 02	CI
Vanta Bioscience Limited Appoints Sangeetha Padam as Company Secretary and Compliance Officer	Apr. 01	CI
Vanta Bioscience Bags INR5.7 Million Order for Good Laboratory Practices Studies	Dec. 03	MT
Vanta Bioscience Limited Receives Order of INR 5.7 Million from Singapore Company to Carry Out GLP Studies	Dec. 01	CI
Vanta Bioscience Limited Approves the Change in Designation of Vyasmurti Madhavrao Shingatgeri from Whole Time Director to Non-Executive Director	Nov. 14	CI
Vanta Bioscience Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 14	CI
Vanta Bioscience Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-08-10	CI
Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance Officer	23-07-10	CI
Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance Officer	22-09-15	CI
Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance Officer	22-09-03	CI
Vanta Bioscience Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Vanta Bioscience to Conduct Animal and Agrochem Studies for Coromandel International	22-01-04	MT
Vanta Bioscience Limited Receives Order of INR 11.8 Million from Coromandel International Limited	22-01-04	CI
Vanta Bioscience Limited Announces CFO Changes	21-11-11	CI
Vanta Bioscience Limited Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-11	CI
Vanta Bioscience : Receives Full Accreditation from AAALAC Council	21-09-14	MT
Vanta Bioscience : Gains Indian Accreditation to Board's Recommendation to Continue Biological Testing	21-07-14	MT
Vanta Bioscience Limited Reports Earnings Results for the Full Year Ended March 31, 2021	21-06-28	CI
Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as CEO	21-01-04	CI
Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as Director	21-01-04	CI
Vanta Bioscience Limited Enters into Commercial Agreement with One of the Leading German Testing Agency	20-11-13	CI
Vanta Bioscience Limited Reports Earnings Results for the Half Year Ended September 30, 2020	20-11-13	CI
1,150,000 Equity Shares of Vanta Bioscience Limited are subject to a Lock-Up Agreement Ending on 10-OCT-2020.	20-10-09	CI
Vanta Bioscience Limited Reports Earnings Results for the Full Year Ended March 31, 2020	20-06-30	CI

Chart Vanta Bioscience Limited

Duration

Period

More charts

Vanta Bioscience Limited is an India-based preclinical contract research company. The Company is providing services of testing and contract research in the fields of clinical research, pre-clinical research, biopharma services, analytical testing and research and environmental studies. It offers a host of preclinical safety assessment services for clientele from pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. In addition, it also provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VANTA BIOSCIENCE LIMITED	+23.53%	4.77M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.43%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B